The first shipment containing 5,040 packs of Molnupiravir, the oral anti-viral treatment for COVID-19, arrived in the Sultanate from Singapore last night.
The Ministry of Health (MoH) has procured 25,000 Molnupiravir packs from Merck, a United States (US) manufacturer.
The US Food and Drug Administration and Brunei Darussalam Medicines Control Authority (BDMCA) have green-lighted Molnupiravir for emergency use authorisation (EUA). High-risk COVID-19 patients will be given access to Molnupiravir to reduce the risk of developing severe symptoms. A doctor will first assess a patient to determine if he/she is a suitable candidate. Each pack lasts for five days.